The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kostenko E.V.

Poliklinika vosstanovitel'nogo lecheniia #7;
Kafedra nevrologii i neĭrokhirurgii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta;
Kafedra nevrologii Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Treatment of a spastic increase of muscle tone in multiple sclerosis with botulinum toxin

Authors:

Kostenko E.V., Boĭko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(7): 89‑93

DOI: 10.17116/jnevro20181187189

Read: 14193 times

Contact the author
Table of contents

TREATMENT OF A SPASTIC INCREASE OF MUSCLE TONE IN MULTIPLE SCLEROSIS WITH BOTULINUM TOXIN
TREATMENT OF A SPASTIC INCREASE OF MUSCLE TONE IN MULTIPLE SCLEROSIS WITH BOTULINUM TOXIN

To cite this article:

Kostenko EV, Boĭko AN. Treatment of a spastic increase of muscle tone in multiple sclerosis with botulinum toxin. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(7):89‑93. (In Russ.)
https://doi.org/10.17116/jnevro20181187189

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Mole­cular mechanisms of acute disseminated ence­phalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Resu­lts of a 5-year project for the early diagnosis of multiple scle­rosis in first-line blood rela­tives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Features of the clinical course of multiple scle­rosis as a factor in persistent disa­bility. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44
Quantitative analysis of cere­brospinal fluid flow in multiple scle­rosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):45-50
Resu­lts of 4 years of therapy with divo­zilimab in patients with rela­psing multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):51-59
Study of neurodegeneration in multiple scle­rosis using opti­cal cohe­rence tomo­graphy of the retina and magnetic reso­nance morphometry of the brain. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):66-72
Evaluation of the effect of highly effe­ctive multiple scle­rosis disease-modifying drugs on the progression of the disease using diffusion-weighted magnetic reso­nance imaging with tractography. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):73-78
Evaluation of the effe­ctiveness of inte­nsive medi­cal reha­bilitation in MS patients through the prism of functional tests and serum neurofilaments. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):79-83
Abstract:

The article presents data of the reviews, consensus and recommendations on the use of botulinum toxin type A (BTA) in multiple sclerosis (MS) patients with spasticity syndrome. It presents the results of randomized clinical trials that confirm the efficacy and favorable safety profile of dysport in treatment of MS patients. The complex approach to spasticity therapy and rehabilitation in MS is discussed.

Keywords:

multiple sclerosis
symptomatic therapy
spasticity
botulinum toxin

Authors:

Kostenko E.V.

Poliklinika vosstanovitel'nogo lecheniia #7;
Kafedra nevrologii i neĭrokhirurgii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta;
Kafedra nevrologii Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Close metadata

References:

  1. Gusev EI, Zavalishin IA, Boyko AN, Zacharova MN. Demyelinating diseases of the central nervous system. In Neurology (National reccomendations, 2nd edition). Ed. by Gusev EI, Konovalov AN, Skvortsova VI. V. 1. M.: GEOTAR-Media; 2018. (In Russ.)
  2. Boiko AN, Kukel’ TM, Lysenko MA, Vdovichenko TV, Gusev EI. Clinical epidemiology of multiple sclerosis in Moscow. Descriptive epidemiology in population of one region of Moscow. Zh nevrologii i psikhiatrii im. S.S. Korsakova. 2013;10(2):8-14. (In Russ.)
  3. Kobelt G, Thompson A, Gannedahl M, Gannedahl M, Eriksson J; MSCOI Study Group; European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123-1136. https://doi.org/10.1177/1352458517694432
  4. Boyko A, Kobelt G, Berg J, Boyko O, Popova E, Capsa D, Eriksson J, The European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia. Mult Sler. 2017;23(2)155-165. https://doi.org/10.1177/1352458517708668
  5. Boyko A, Kesselring J, Paty DW, Siva A, Singhal B, Thompson A, Willoughby E. Multiple sclerosis and public health. Educational and management implications. World Health Organization, Department of Mental Health, Neuroscience and Neurological Disorders. 1999;2:1-11.
  6. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10(5):589-595.
  7. Pozzilli C. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Rev Neurother. 2013;13(12):49-54. https://doi.org/10.1586/14737175.2013.865877
  8. Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther. 2009;26(12):1043-1057. https://doi.org/10.1007/s12325-009-0082-x
  9. Cheung J, Rancourt A, Di Poce S, Levine A, Hoang J, Ismail F, Boulias C, Phadke CP. Patient-identified factors that influence spasticity in people with stroke and multiple sclerosis receiving botulinum toxin injection treatments. Physiotherapy Can. 2015;67(2);157-166. https://doi.org/10.3138/ptc.2014-07
  10. Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM. 2004;97(10):671-676.
  11. Gusev EI, Boyko AN, Kostenko EV. Spasticity: clinic, diagnostic and complex rehabilitation with botulintoxin. M.: GEOTAR-Media; 2017. (In Russ.)
  12. Local damage of the brain in adults: spasticity syndrome. Pod red. Khat'kovoi EM.: MEDpress-inform; 2017. (In Russ.)
  13. Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, Walker H, Marciniak C, Deltombe T, Skoromets A, Khatkova S, Edgley S, Gul F, Catus F, De Fer BB, Vilain C, Picaut P; International Abobotulinumtoxin A Adult Upper Limb Spasticity Study Group. Safety and efficacy of abobotulinumtoxin A for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomized controlled trial. Lancet Neurol. 2015;14(10):992-1001. https://doi.org/10.1016/S1474-4422(15)00216-1
  14. Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-1826. https://doi.org/10.1212/WNL.0000000000002560
  15. Gracies JM, Esquenazi A, Brashear A, Banach M, Kocer S, Jech R, Khatkova S, Benetin J, Vecchio M, McAllister P, Ilkowski J, Ochudlo S, Catus F, Grandoulier AS, Vilain C, Picaut P; International AbobotulinumtoxinA Adult Lower Limb Spasticity Study Group. Efficacy and safety of abobotulinumtoxin A in spastic lower limb: Randomized trial and extension. Neurology. 2017;89(22):2245-2253. https://doi.org/10.1212/WNL.0000000000004687
  16. Cameron MH, Bethoux F, Davis N, Frederick M. Botulinum toxin for symptomatic therapy in multiple sclerosis Curr Neurol Neurosci Rep. 2014;14(8):463. https://doi.org/10.1007/s11910-014-0463-7
  17. Kostenko EV, Batisheva TT, Riabukchina OV, Petrova LV, Boyko AN. Current wat of treatment of spastic muscle tonus with botulin toxin. M.: Real-taim; 2011. (In Russ.)
  18. Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, Poewe W, Wissel J, Bain P, Glickman S, Sayer A, Richardson A, Dott C. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000;68:707-712.
  19. Habeka M, Karni A, Balash Y, Gurevich T. The place of the botulinum toxin in the management of multiple sclerosis. Clin Neurol Neurosurg. 2010;112:592-596. https://doi.org/10.1016/j.clineuro.2010.04.010
  20. Gusev YI, Banach M, Simonow A, Skoromets A, Czlonkowska A, Shmidt T, Bojakowski J, Fryze W, Haase J, Judith Haas, Nowicki J, Johann Hagenah, Hans W. Kölmel, Christian Neumann & Sofia L Timirbaeva. Efficacy and safety of botulinum type a toxin in adductor spasticity due to multiple sclerosis. J Musculoskeletal Pain. 2008;16(3):175-188. https://doi.org/10.1080/10582450802161952
  21. Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, SoelbergSørensen P, Thompson AJ, Vermersch P, Gold R, Montalban X. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Mult Scler. 2016;22(11):1386-1396. https://doi.org/10.1177/1352458516643600
  22. Dressler D, Bhidayasiri R, Bohlega S, Chahidi A, Chung TM, Ebke M, Jacinto LJ, Kaji R, Koçer S, Kanovsky P, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sagástegui-Rodríguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Saberi FABotulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. J Neurol. 2016;264(1):112-120. https://doi.org/10.1007/s00415-016-8304-z
  23. Gold R, Oreja-Guevara C. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Rev Neurother. 2013;13(12):55-59. https://doi.org/10.1586/14737175.2013.865880
  24. Safarpour Y, Mousavi T, Jabbari B. Botulinum toxin treatment in multiple sclerosis, a review. Curr Treat Options Neurol. 2017;19(10):33. https://doi.org/10.1007/s11940-017-0470-5
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.